First- or second-line treatment for HIV-MCD
| . | n . | Sustained CR, yes/no . | Sustained CR . | No sustained CR . |
|---|---|---|---|---|
| First-line | ||||
| Cytostatics only (C) | 16 | 7/9 | Dox (2), Eto (2), CHOP (1), CHOP + Eto (1), Eto + Dox + Bleo (1) | Dox (2), Eto (2), CHOP (2), Eto + Dox + Bleo (2), Eto + Vin (1) |
| Cytostatics plus antivirals (C + V) | 6 | 2/4 | CHOP + Fos/Cid (1), CHOP + Val/Cid (1) | Dox + Val (2), CHOP + Fos (1), CHOP + Val (1) |
| Cytostatics plus rituximab (C + R) or rituximab monotherapy (R) | 16 | 10/1† | R (7), R-CHOP (2), Dox + R (1) | R (1) |
| Antivirals only (V) | 6 | 2/4 | Val (2) | Val (1), Val/Cid (1), Fos + IFN (1), Fos (1) |
| No or other therapy | 8 | 1/7 | Splenectomy (1) | Splenectomy (1), no treatment (6) |
| Second-line* | ||||
| Cytostatics only (C) | 2 | 1/1 | Dox (1) | Chlorambucil + Pred (1) |
| Cytostatics plus antivirals (C + V) | 1 | 1/0 | CHOP + Val (1) | |
| Cytostatics plus rituximab (C + R) or rituximab monotherapy (R) | 4 | 3/1 | R (2), Benda + R (1) | R (1) |
| . | n . | Sustained CR, yes/no . | Sustained CR . | No sustained CR . |
|---|---|---|---|---|
| First-line | ||||
| Cytostatics only (C) | 16 | 7/9 | Dox (2), Eto (2), CHOP (1), CHOP + Eto (1), Eto + Dox + Bleo (1) | Dox (2), Eto (2), CHOP (2), Eto + Dox + Bleo (2), Eto + Vin (1) |
| Cytostatics plus antivirals (C + V) | 6 | 2/4 | CHOP + Fos/Cid (1), CHOP + Val/Cid (1) | Dox + Val (2), CHOP + Fos (1), CHOP + Val (1) |
| Cytostatics plus rituximab (C + R) or rituximab monotherapy (R) | 16 | 10/1† | R (7), R-CHOP (2), Dox + R (1) | R (1) |
| Antivirals only (V) | 6 | 2/4 | Val (2) | Val (1), Val/Cid (1), Fos + IFN (1), Fos (1) |
| No or other therapy | 8 | 1/7 | Splenectomy (1) | Splenectomy (1), no treatment (6) |
| Second-line* | ||||
| Cytostatics only (C) | 2 | 1/1 | Dox (1) | Chlorambucil + Pred (1) |
| Cytostatics plus antivirals (C + V) | 1 | 1/0 | CHOP + Val (1) | |
| Cytostatics plus rituximab (C + R) or rituximab monotherapy (R) | 4 | 3/1 | R (2), Benda + R (1) | R (1) |
A sustained complete remission (CR) was defined as the absence of MCD symptoms for at least 12 months.
Dox indicates doxorubicin; Eto, etoposide; Bleo, bleomycin; Fos, foscarnet; Cid, cidofovir; Val, valgancyclovir; Benda, bendamustine; Vin, vincristine; IFN, interferon; and Pred, prednisolone.
Four patients received multiple treatment regimens for HIV-MCD.
In 5 patients (4 × R, 1 × Eto + R + Val), follow-up was too short for outcome analysis (all were in CR at the last follow-up).